[Federal Register Volume 81, Number 126 (Thursday, June 30, 2016)]
[Notices]
[Page 42718]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-15442]
[[Page 42718]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Department of Health and Human
Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by emailing the indicated licensing contact at the National Heart,
Lung, and Blood, Office of Technology Transfer and Development Office
of Technology Transfer, 31 Center Drive, Room 4A29, MSC2479, Bethesda,
MD 20892-2479; telephone: 301-402-5579. A signed Confidential
Disclosure Agreement may be required to receive any unpublished
information.
SUPPLEMENTARY INFORMATION: Technology description follows.
Long Acting Therapeutic Conjugates With Evans Blue
This invention is a platform technology that pertains to the
advantages of conjugating therapeutics to Evans Blue thus providing
long lasting pharmacokinetic profiles by complexing with albumin.
Notably, albumin bound therapeutic- or prodrug-Evans Blue conjugates
provide a complex with a total molecular size above 60 kDa thus
eliminating the risk for renal clearance. Interestingly, since albumin
also crosses the blood-brain barrier and since all circulating Evans
Blue is bound to albumin, Evans Blue bound therapeutics or prodrugs can
also cross the blood-brain barrier. By way for example but not
limitation, Evans Blue can be conjugated to insulin, GLP-1, exendin-4,
exendin (9-39), octreotide, bombesin, RGD peptide
(arginylglycylaspartic acid), vascular endothelial growth factor
(VEGF), interferon (IFN), tumor necrosis factor (TNF), asparaginase, or
adenosine deaminase, exenatide, dipeptidyl peptidase-4 inhibitors,
neuropilin, epidermal growth factor, islet neogenesis associated
protein, alpha-1 antitrypsin, anti-inflammatory agents, glulisine,
glucagons, local cytokines, modulators of cytokines, anti-apoptotic
molecules, aptamers, asparaginase, adenosine deaminase, interferon
[alpha]2a, interferon [alpha]2b, granulocyte colony stimulating factor,
growth hormone receptor antagonists, doxorubicin, paclitaxel,
gemcitabine, camptothecin, and temozolomide. Evans Blue conjugates
according to this invention can additionally include radionuclides like
\18\F, \76\Br, \124\I, \125\I, or \131\I, or \117m\Sn for tracking or
use in diagnostics.
Potential Commercial Applications:
--Diabetes therapeutics
--Cancer therapeutics
--CNS therapeutics
--Pharmacokinetic/distribution studies
Competitive Advantages:
--long pharmacokinetic profile
--no renal clearance of circulating drug
Development Stage:
Early stage
Inventors: Xiaoyuan Chen, Lixin Lang, Gang NIU (all of NIBIB).
Intellectual Property: HHS Reference No. E-143-2015/0; U.S.
Provisional Patent Application 62/182,694 filed June 22, 2015;
International Patent Application PCT/US2016/38475 filed June 21, 2016.
Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019;
[email protected].
Dated: June 23, 2016.
Michael Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood
Institute, Office of Technology Transfer and Development.
[FR Doc. 2016-15442 Filed 6-29-16; 8:45 am]
BILLING CODE 4140-01-P